Skip to main content

Logo
  • Live News iconLive News
  • Smart Screener iconSmart Screener
  • Trade Opportunities iconTrade Opportunities
  • Alpha Watch iconAlpha Watch
  • Catalyst iconCatalyst
Skip to main content
Stock Ask Logo
Hi, Guest User

Log in or create an account to get full access

Open an Account (opens in a new window)

TOOLS

Live News
Smart Screener
Trade Opportunities
Alpha Watch
Catalyst

StockkASK powered by Indira Securities

Pramodini Medicare Ltd (PRAMODINI) Share Price & Fundamentals

Company Overview

Founded Year

2000

Listed Year

-

Headquarter

Vijayawada, India

MD/CEO

-

Website

-

Company Facts

What we do

Pramodini Medicare Ltd provides technology-enabled diagnostic services including radiology, clinical laboratory, and nuclear medicine across public and private hospitals in India.

Founded in

2,000

Market share

-

Problem solved

Offers comprehensive diagnostic and teleradiology services to improve early disease detection and monitoring in healthcare.

Top clients or who we serve

Public and private hospitals, government medical colleges, Public Sector Undertakings, and standalone diagnostic centres.

Key management

-

Our journey and innovations

Started in 2000, transitioned to public limited in 2025, expanded diagnostic offerings and partnerships across Tier I to III cities.

Where we operate

Pan-India, covering Tier I, II, and III cities across India.

Top products or what we offer

Radiology (MRI, CT, X-ray), Clinical Laboratory (hematology, pathology, biochemistry), Nuclear Medicine (PET-CT, SPECT).

Top brands

-

Raw materials needed

-

Raw materials supplier

-

Recurring vs cyclical contribution

Revenue mainly recurring from diagnostic testing and healthcare services.

Our industry position

-

Financial highlights

FY 2023-24 revenue Rs 62.29 Cr, net profit Rs 17.38 Cr.

Geographical revenue split

-

Order book

-

Whats driving growth

Growth driven by expanded public-private partnerships and advanced diagnostic technology adoption.

Our future plans

Filed draft prospectus for IPO to raise capital for business expansion and service enhancement.

Our green promise

-

Our people and values

-

Key challenges ahead

-

Interesting facts

-

Risks and strategy

-

Market Footprint

Top Clients

Top Clients

Public and private hospitals, government medical colleges, Public Sector Undertakings, and standalone diagnostic centres.

Top Products

Top Products

Radiology (MRI, CT, X-ray), Clinical Laboratory (hematology, pathology, biochemistry), Nuclear Medicine (PET-CT, SPECT).

Price Movement & Share Holding

Today's High/Low

109111.6

52 Week High/Low

104137
Past Returns

1 week

-2.15%

1 month

-9.36%

3 month

-7.71%

1 year

-7.71%

3 year

-7.71%

5 year

-7.71%

Share Holding

Promoters

62.64%

FII

0.93%

DII

5.29%

Retail

27.63%

Others

3.52%

Company Overview

Founded Year

2000

Listed Year

-

Headquarter

Vijayawada, India

MD/CEO

-

Website

-

Price Movement & Share Holding

Today's High/Low

109111.6

52 Week High/Low

104137

Past Returns

1 week

-2.15%

1 month

-9.36%

3 month

-7.71%

1 year

-7.71%

3 year

-7.71%

5 year

-7.71%

Share Holding

Promoters

62.64%

FII

0.93%

DII

5.29%

Retail

27.63%

Others

3.52%

Company Facts

What we do

Pramodini Medicare Ltd provides technology-enabled diagnostic services including radiology, clinical laboratory, and nuclear medicine across public and private hospitals in India.

Founded in

2000

Problem solved

Offers comprehensive diagnostic and teleradiology services to improve early disease detection and monitoring in healthcare.

Top clients or who we serve

Public and private hospitals, government medical colleges, Public Sector Undertakings, and standalone diagnostic centres.

Our journey and innovations

Started in 2000, transitioned to public limited in 2025, expanded diagnostic offerings and partnerships across Tier I to III cities.

Where we operate

Pan-India, covering Tier I, II, and III cities across India.

Top products or what we offer

Radiology (MRI, CT, X-ray), Clinical Laboratory (hematology, pathology, biochemistry), Nuclear Medicine (PET-CT, SPECT).

Recurring vs cyclical contribution

Revenue mainly recurring from diagnostic testing and healthcare services.

Financial highlights

FY 2023-24 revenue Rs 62.29 Cr, net profit Rs 17.38 Cr.

Whats driving growth

Growth driven by expanded public-private partnerships and advanced diagnostic technology adoption.

Our future plans

Filed draft prospectus for IPO to raise capital for business expansion and service enhancement.

Market Footprint

Top Clients

Top Clients

Public and private hospitals, government medical colleges, Public Sector Undertakings, and standalone diagnostic centres.

Top Products

Top Products

Radiology (MRI, CT, X-ray), Clinical Laboratory (hematology, pathology, biochemistry), Nuclear Medicine (PET-CT, SPECT).

StockkASK provides smart, AI-powered insights to support analysis. AI can make mistakes; verify independently before investing.Terms & Conditions